Oxygen Containing Reactant Patents (Class 530/410)
-
Publication number: 20130053548Abstract: Protein A crystals and Protein A cross-linked protein crystals (CLPCs) are described. Methods of preparing and using are also disclosed.Type: ApplicationFiled: September 13, 2010Publication date: February 28, 2013Inventors: Bhami Shenoy, Sibyl Baladi, Reena Patel, Margaret McGrath, Nazer Khalaf, Chanchal Randhawa
-
Publication number: 20130040362Abstract: The present invention is directed to a method for producing a biomolecule conjugate where the method is integrated into a single unit operation.Type: ApplicationFiled: February 21, 2011Publication date: February 14, 2013Applicant: BAYER HEALTHCARE LLCInventors: Jens H. Vogel, Chi Shung Brian To, Carolina Lucia Bianco
-
Publication number: 20130041135Abstract: Provided are a filler for affinity chromatography which has excellent alkali resistance, and a method for isolating immunoglobulin. The filler for affinity chromatography is a filler in which a protein represented by the following formula (1) is immobilized on a carrier. R—R2 ??(1) wherein R represents an amino acid sequence consisting of 4 to 300 amino acid residues containing a region consisting of 4 to 20 contiguous histidine residues; and R2 represents an amino acid sequence capable of binding to immunoglobulin, the amino acid sequence consisting of 50 to 500 amino acid residues containing Z domain of Protein A or a fragment thereof, or a variant thereof, provided that the R binds to C-terminus or N-terminus of the R2.Type: ApplicationFiled: March 23, 2011Publication date: February 14, 2013Applicant: JSR CORPORATIONInventors: Kouji Tamori, Tetsuo Fukuta, Masaaki Miyaji, Yong Wang, Takayoshi Abe, Yusuke Okano, Masaki Momiyama, Takahiro Kawai
-
Publication number: 20130034914Abstract: Provided are probes comprising a class 1 release factor conjugated to a fluorescent label and methods of making the probes. Also provided are methods for detecting conformational changes in ribosomes and associated molecules, such as class 1 release factors. In addition, methods of identifying a compound for reducing nonsense-mediated decay of mRNA and/or for inhibiting termination of protein synthesis at a premature stop codon, are described. Methods of assaying RF3 activity are also included.Type: ApplicationFiled: February 28, 2012Publication date: February 7, 2013Inventors: Ruben L. GONZALEZ, JR., Samuel H. STERNBERG, Dileep K. PULUKKUNAT
-
Publication number: 20130017597Abstract: Use of a biological photoreceptor as light-controlled ion channel for the alteration of the ion conductivity of a membrane by means of light. The photoreceptor used comprises an apoprotein and a light-sensitive polyene covalently bound to the apoprotein, said polyene interacting with the apoprotein and functioning as a light-sensitive gate.Type: ApplicationFiled: April 23, 2012Publication date: January 17, 2013Applicant: MAX-PLANCK-GESEL. ZUR FOERDERUNG DER WISSEN. EV.Inventors: Peter Hegemann, Georg Nagel, Ernst Bamberg
-
Publication number: 20130011432Abstract: The invention is directed to an adenovirus-antigen conjugate comprising (a) a disrupted adenovirus with a coat protein and (b) an antigen conjugated to the coat protein of the disrupted adenovirus, as well as a conjugate comprising (a) a disrupted adenovirus with a coat protein and (b) an antigen conjugated to the coat protein of the disrupted adenovirus. The invention also provides a method of inducing an immune response against an antigen in a human using the aforementioned conjugates. The invention further provides an adeno-associated viral vector comprising a nucleic acid sequence which encodes an antibody directed against cocaine.Type: ApplicationFiled: March 17, 2011Publication date: January 10, 2013Applicant: CORNELL UNIVERSITY (CCTEC)Inventors: Ronald G. Crystal, Bishnu De, Martin Hicks, Jonathan Rosenberg, Stephen M. Kaminsky
-
Publication number: 20120329127Abstract: The present disclosure relates to materials and methods of conjugating a water soluble polymer to a therapeutic protein.Type: ApplicationFiled: May 25, 2012Publication date: December 27, 2012Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: Juergen Siekmann, Alfred Weber, Hanspeter Rottensteiner, Peter Turecek
-
Publication number: 20120329176Abstract: Indirectly labelled assay conjugates prepared by a method that includes the step of submitting the binding member comprised by the conjugate to denaturing conditions prior to labelling the binding member. The indirectly labelled assay conjugates demonstrate an increased sensitivity when employed in diagnostic assays compared to assay conjugates prepared by methods that do not include a step of submitting the binding member to denaturing conditions prior to labelling. Processes for the preparation of the indirectly labelled assay conjugates, methods of detecting an analyte comprising the use of the indirectly labelled assay conjugate and kits comprising the indirectly labelled conjugates are also provided.Type: ApplicationFiled: August 31, 2012Publication date: December 27, 2012Applicant: ABBOTT LABORATORIESInventors: Anthony S. Muerhoff, Suresh M. Desai, Thomas P. Leary, George J. Dawson, Robin A. Gutierrez
-
Patent number: 8329675Abstract: The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.Type: GrantFiled: March 16, 2011Date of Patent: December 11, 2012Assignee: Infinity Pharmaceuticals, Inc.Inventors: Julian Adams, Mark L. Behnke, Alfredo C. Castro, Catherine A. Evans, Louis Grenier, Michael J. Grogan, Tao Liu, Daniel A. Snyder, Thomas T. Tibbitts
-
Publication number: 20120296072Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.Type: ApplicationFiled: August 2, 2012Publication date: November 22, 2012Applicant: AMGEN INC.Inventors: Olaf B. Kinstler, Nancy Elise Gabriel, Christine E. Farrar, Randolph B. DePrince
-
Publication number: 20120295287Abstract: This document provides methods and materials related to detecting neurotransmitters and other biologically active small molecules. For example, methods for detecting and measuring hapten levels in a biological sample using antibodies specific for conjugated haptens are provided.Type: ApplicationFiled: November 8, 2010Publication date: November 22, 2012Applicant: Pharmasan Labs, Inc.Inventors: Gottfried H. Kellermann, Han J.G. Huisman
-
Publication number: 20120288445Abstract: Compounds of the formula (I) are disclosed: 18F—(CHR)n(CH2)mCHO??(I) in which n and m are independently 0 and 1 with at least one of n and m being 1, and R (if present) is a hydrogen atom or a methyl group, subject to the proviso that if n is 1 and R is methyl then m is 0. Synthesis of the compounds is described together with their use in radiolabelling reactions, e.g. for the radiolabelling of peptides to facilitate detection by Positron Emission Tomography (PET) imaging. The preferred compound is [18F]Fluoroacetaldehyde.Type: ApplicationFiled: April 13, 2012Publication date: November 15, 2012Applicant: The University of ManchesterInventor: Christian PRENANT
-
Publication number: 20120269895Abstract: A polyion Complex (PIC) polymeric micelle is formed by interaction between a bioactive protein and a dendritic block copolymer of opposite charge. The conventional low stability of PIC micelles with bioactive proteins vis-à-vis ionic strength is offset by the stability provided by the dendritic block. The overall process for preparing the micelles is facilitated by the simplicity of the drendritic block copolymer synthesis.Type: ApplicationFiled: July 22, 2010Publication date: October 25, 2012Applicant: Universidade De Santiago De CompostelaInventors: Ana Sousa Herves, Eduardo Fernandez Megia, Ricardo Riguera Vega
-
Publication number: 20120270801Abstract: The disclosure provides a HER3 binding polypeptide, comprising a HER3 binding motif, BM, which motif consists of the amino acid sequence selected from i) EX2X3X4A X6X7EIW X11LPNL X16X17X18QX20 X21AFIX25 X26LX28D, and ii) an N amino acid sequence which has at least 90% identity to the sequence defined in i), wherein the polypeptide binds to the extra-cellular domain of HER3. Also provided is a bispecific ligand having binding affinity for HER3 and for HER2, or for HER3 and for EGFR, and comprising a HER3. binding polypeptide as defined herein and a HER2 binding polypeptide or a EGFR binding polypeptide.Type: ApplicationFiled: October 27, 2010Publication date: October 25, 2012Applicant: AFFIBODY ABInventors: Fredrik Frejd, Elin Gunneriusson, Nina Kronqvist, John Löfblom, Stefan Ståhl
-
Patent number: 8273833Abstract: The present invention is directed to branched reactive water-soluble polymers comprising at least two polymer arms, such as poly(ethylene glycol), attached to a central aliphatic hydrocarbon core molecule through ether linkages. The branched polymers bear at least one functional group for reacting with a biologically active agent to form a biologically active conjugate. The functional group of the branched polymer can be directly attached to the aliphatic hydrocarbon core or via an intervening linkage, such as a heteroatom, -alkylene-, —O-alkylene-O—, -alkylene-O-alkylene-, -aryl-O—, —O-aryl-, (—O-alkylene-)m, or (-alkylene-O—)m linkage, wherein m is 1-10.Type: GrantFiled: December 8, 2010Date of Patent: September 25, 2012Assignee: Nektar TherapeuticsInventors: Michael David Bentley, Xuan Zhao, Xiaoming Shen, William Dudley Battle, III
-
Publication number: 20120222584Abstract: Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. Phase invertible compositions in accordance with the invention are prepared by combining a liquid proteinaceous substrate and a liquid crosslinking composition, where the liquid crosslinking composition includes a macromolecular crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications.Type: ApplicationFiled: May 15, 2012Publication date: September 6, 2012Applicant: Tenaxis Medical, Inc.Inventors: Ronald Dieck, Ian J. Handley, Neil Winterbottom, Joanna Wong
-
Publication number: 20120208258Abstract: The present invention relates to a conjugate of a protein or peptide with a polyethylene glycol derivative having catechol, wherein the protein or peptide is mono-PEGylated at the N-terminal with the polyethylene glycol derivative, and to a preparation method thereof. According to the invention, the catechol-PEG derivative can be site-specifically conjugated with the N-terminal amine group of a protein or peptide, so that a homogeneous polyethylene glycol-protein or -peptide conjugate can be obtained in high yield. Unlike a prior art conjugate, the conjugate obtained according to the invention allows the decrease in the activity of the protein to be minimized without chemically modifying the protein, and thus the conjugate has an excellent pharmacological effect. Also, because the conjugate is homogeneous, the process for preparing the conjugate can be simplified. Moreover, the conjugate has uniform biological efficacy in vivo and shows strong resistance to hydrolysis and thus a long in vivo duration time.Type: ApplicationFiled: October 29, 2010Publication date: August 16, 2012Inventors: Haeshin Lee, Hyukjin Lee, In Taek Song, Moon Sue Lee
-
Publication number: 20120190097Abstract: The present invention is directed to compositions comprising a polymer backbone with protective chain and anionic groups, and a cationic therapeutic agent. The present invention is directed to compositions for treating infections, inflammatory diseases, excess growth, and damaged cells and organs.Type: ApplicationFiled: September 8, 2010Publication date: July 26, 2012Inventors: Gerardo M. Castillo, Elijah M. Bolotin, Akiko Nashimoto-Ashfield
-
Publication number: 20120178913Abstract: A method for the modification of an amino acid, protein or peptide is disclosed. The method comprises reacting a carbon-carbon double bond-containing compound with an amino acid, a protein or a peptide containing an allyl sulfide group in the presence of a catalyst which promotes olefin metathesis, to form a modified amino acid, protein or peptide. Preferred carbon-carbon double bond-containing compounds include carbohydrates.Type: ApplicationFiled: June 5, 2009Publication date: July 12, 2012Applicant: ISIS INNOVATION LIMITEDInventors: Yuya Angel Lin, Justin Mark Chalker, Benjamin Guy Davis
-
Publication number: 20120178914Abstract: The invention provides methods for the PEGylation of an N-terminal cysteine of a polypeptide such that the thiol group of the cysteine is unreacted in the fmal PEGylated polypeptide. In one embodiment, the invention comprises a method of PEGylating a polypeptide having an N-terminal cysteine, the method comprising: contacting the polypeptide with a polyethylene glycol (PEG) derivative having a free aldehyde group in a reaction mixture under reducing conditions such that the N-terminal cysteine in the resultant PEGylated polypeptide has a free thiol group.Type: ApplicationFiled: September 21, 2010Publication date: July 12, 2012Applicant: VYBION, INC.Inventors: Lee A. Henderson, G. Scott Fletcher
-
Publication number: 20120135459Abstract: The present invention relates to novel fluorinated 3,6-diaminoxanthene compounds derived from the basic structural formula (I) and to their uses as photostable fluorescent dyes, e.g. for immunostainings and spectroscopic and microscopic applications, in particular in conventional microscopy, stimulated emission depletion (STED) reversible saturable optically linear fluorescent transitions (RESOLFT) microscopy, and fluorescence correlation spectroscopy. The claimed compounds are also useful as molecular probes in various spectroscopic applications.Type: ApplicationFiled: June 26, 2009Publication date: May 31, 2012Applicant: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.Inventors: Stefan W. Hell, Vladimir N. Belov, Gyuzel Mitronova, Mariano Bossi, Gael Moneron, Christian A. Wurm, Stefan Jakobs, Christian Eggeling, Jakob Bierwagen, Lars Meyer
-
Patent number: 8188225Abstract: Binding of inorganic phosphate to a phosphate binding protein can result in changes to the stacking of appropriately positioned chromophores, thereby resulting in a detectable change. The invention provides a phosphate-binding protein that undergoes a conformational change from an initial conformation to a final conformation upon binding of phosphate, wherein the protein carries a first label and a second label, and wherein the first and second labels are arranged such that they exhibit molecular stacking that is perturbed on changing from one conformation to the other. Preferred labels are rhodamines.Type: GrantFiled: August 31, 2006Date of Patent: May 29, 2012Assignee: Medical Research CouncilInventors: John Edgar Thomas Corrie, Martin Ronald Webb, Michael Prince Okoh
-
Publication number: 20120115169Abstract: Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol.Type: ApplicationFiled: November 9, 2010Publication date: May 10, 2012Applicant: ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC.Inventors: Michael C. Mullenix, Robert Elliot Zipkin, Jeffrey Kroll Adams, Wayne Forrest Patton, James J. Donegan
-
Publication number: 20120108548Abstract: This invention provides novel compositions to inhibit the aggregation of amyloid proteins. In various embodiments the compositions comprise a molecular tweezers that binds lysine and/or arginine and thereby inhibits the aggregation of amyloidogenic proteins.Type: ApplicationFiled: March 5, 2010Publication date: May 3, 2012Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, UNIVERSITÄT DUISBURG-ESSEN, MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Gal Bitan, Akila Shanmugam, Aleksey Lomakin, Thomas Schrader, Frank Gerrit Klarner, Peter Talbiersky, Jolanta Polkowska, Frank Bastkowski, Sharmistha Sinha, Sally Frautschy
-
Publication number: 20120093877Abstract: A bioscaffold and method of manufacture is described. The bioscaffold comprised greater than 80% type I collagen fibers or bundles having a knitted structure providing tensile load strength. The method of manufacture comprises the steps of: (a) isolating collagen fibers or bundles; (b) incubating said fibers or bundles in a mixture of NaOH, alcohol, acetone, HC; and ascorbic acid; and (c) mechanical manipulation of said fibers or bundles to produce a knitted structure.Type: ApplicationFiled: July 24, 2009Publication date: April 19, 2012Applicant: THE UNIVERSITY OF WESTERN AUSTRALIAInventor: Ming Hao Zheng
-
Patent number: 8153135Abstract: Disclosed is a method of producing a polysaccharide-polypeptide conjugate by reacting a polysaccharide with a polypeptide which contains at least one free amino group, wherein a polysaccharide carrier comprising vicinal hydroxyl groups is oxidized under ring opening to create vicinal aldehyde groups and is reacted with one or more base-instable antigenic polypeptide(s) containing at least one free amino group, the polypeptide(s) being bound directly to the polysaccharide carrier via at least one azomethine bond.Type: GrantFiled: September 13, 2005Date of Patent: April 10, 2012Inventors: Hans Loibner, Helmut Eckert
-
Publication number: 20120084871Abstract: The present invention provides, in part, NPC1L1 from various species. Methods of using the NPC1L1 polypeptides and polynucleotide set forth herein, e.g., in screening assays, are also set forth.Type: ApplicationFiled: February 14, 2011Publication date: April 5, 2012Applicant: Schering CorporationInventors: Scott Altmann, Xiaorui Yao, Kim Anne O'Neill, Brian E. Hawes
-
Patent number: 8148501Abstract: Absorbent hydrogels are formed by reacting a protein meal base, a radical initiator and a polymerizable monomer. Optionally, a cross-linking agent and/or a radical accelerant, such as tetramethylethylenediamine (TMEDA) or sodium bisulfite (NaHSO3), is also added to the mixture. Preferably, the radical initiator is ammonium persulfate (APS) or potassium persulfate (KPS), and the cross-linking agent is preferably trifunctional trimethylolpropane trimethacrylate (TMPTMA) or methylene bis acrylamide (MBA). The polymerizable monomer is preferably acrylic acid, or a combination of acrylic acid and acrylamide. The as-formed hydrogel is washed in order to extract non-reactant components from the gel and then dried. The resultant absorbent and superabsorbent hydrogels have high water uptake ratios, and can be utilized for a variety of applications.Type: GrantFiled: February 23, 2009Date of Patent: April 3, 2012Assignee: Battelle Memorial InstituteInventors: Herman P. Benecke, Bhima R. Vijayendran, Kevin B. Spahr
-
Publication number: 20120065344Abstract: A modified compound that has at least one further functional group, in particular a bio- or macromolecule, comprising at least one x-fold (x?1) chemoselectively incorporated phosphoramidate group of general formula (I), NPO(OR1) (OR1?), and/or at least one x-fold (x?1) chemoselectively incorporated phosphonamide group of general formula (Ia), NPO(R1)(OR1?). R1 and R1? is selected from the group containing glycerol, polyglycerol, PEG polymers of the general empirical formula C2nH4n+2On+1 with n?1, Cn-alkyl chains with n?1; functionalized Cn-alkyl chains with n?1, aryls, heteroaryl, silyl, lipids, fluorophores, saccharides, peptides, crown ethers, or a linker, which links the aforementioned groups. R1 and R1? can be identical to or different from one another.Type: ApplicationFiled: March 9, 2010Publication date: March 15, 2012Applicant: FREIE UNIVERSITAET BERLINInventors: Christian Hackenberger, Giuseppe Del Signore, Remigiusz Serwa, Ina Wilkening, Robert Vallee
-
Coenzyme Q10 Nanoparticles, Preparation Method Thereof and Composition Containing Said Nanoparticles
Publication number: 20120041178Abstract: Provided are a coenzyme Q10 nanoparticle, a method of preparing the same and a composition having the nanoparticle. According to the present invention, Coenzyme Q10 may be dissolved in only a water-miscible organic solvent, and easily made into a nano-sized particle and solubilized under a low energy condition, for example, by simple stirring. The coenzyme Q10 may be dispersion-stabilized by an amino acid or protein. The coenzyme Q10 is formed in a nano-sized particle and solubilized, an absorption rate may be increased and simultaneously deliver the amino acid and protein with the nanoparticle. Thus, the coenzyme Q10 nanoparticle can be effectively used in food, cosmetics and medicine.Type: ApplicationFiled: April 6, 2010Publication date: February 16, 2012Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Bong Hyun Chung, Jung Hyun Han -
Publication number: 20120009190Abstract: The invention provides isolated Pre-Ligand Assembly Domain (PLAD) polypeptides comprising an amino acid sequence of a domain (e.g., a Fibronectin Ill-like domain) of an IL-17 Receptor (IL-17R) family member, wherein the PLAD polypeptide inhibits multimerization of a receptor complex comprising an IL-17R family member. Also provided are isolated PLAD-binding polypeptides, e.g., antibodies and avimers, which specifically bind to a PLAD polypeptide described herein. Related chimeric proteins, conjugates, nucleic acids, vectors, and host cells are provided herein. Further provided are methods of treating an inflammatory or autoimmune disease, methods of inhibiting IL-17-mediated signal transduction, methods of inhibiting IL-17 ligand binding, methods of inhibiting multimerization of IL-17R complexes, and methods of inhibiting the production of at least one cytokine, chemokine, matrix metalloproteinase, or other molecule associated with IL-17 signal transduction are provided.Type: ApplicationFiled: April 20, 2008Publication date: January 12, 2012Applicant: AMGEN INC.Inventors: Sarah L. Gaffen, Fang Shen, Walter Hanel, Jill Kramer, James P. Malone, Michael Wittekind, Raymond Paxton
-
Patent number: 8092811Abstract: The present invention relates to surface proteins of Moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their ability to inhibit the complement system. These surface proteins are useful in the preparation of vaccines. The present invention also provides peptides interacting with fibronectin, laminin and the complement system.Type: GrantFiled: August 8, 2006Date of Patent: January 10, 2012Assignee: Arne Forsgren ABInventors: Arne Forsgren, Kristian Riesbeck
-
Publication number: 20110318421Abstract: The present disclosure is directed to surface functionalized ceramic nanoparticles. The method for producing the surface functionalized ceramic nanoparticles generally includes at least four distinct steps: 1) synthesis of an amphiphilic surfactant having the desired surface functionality, 2) formation of mixed solvent microstructured solution with the surfactant, 3) synthesis of the desired ceramic within the microstructured solution, and 4) chemical attachment of the surfactant to the ceramic nanoparticle. The composition of the surface functionalized nanoparticle comprises a lipophilic component, a hydrophilic component, a chelating agent and a ceramic forming component.Type: ApplicationFiled: August 8, 2011Publication date: December 29, 2011Inventor: Edward Parsonage
-
Patent number: 8071789Abstract: The present invention features biarsenical molecules. Target sequences that specifically react with the biarsenical molecules are also included. The present invention also features kits that include biarsenical molecules and target sequences. Tetraarsenical molecules are also featured in the invention.Type: GrantFiled: March 18, 2009Date of Patent: December 6, 2011Assignee: The Regents of the University of CaliforniaInventors: Roger Y. Tsien, B. Albert Griffin
-
Patent number: 8067374Abstract: Disclosed is an adhesive hemostatic agent based on non-blood constituents including DOPA, able to strongly adhere to collagen fibers. The agent includes an antifibrinolytic agent in addition to an esterified atelocollagen which is non-immunogenic and may become positively charged thereon such that the adhesive hemostatic agent has no possibility of mediating particular diseases or viral infections (HIV, HCV, HBV, CMV, etc), unlike conventional agents comprising blood constituents, and readily binds to negatively charged platelets at high adhesive strength, thus inducing quick blood coagulation. Also, provided is a method for preparing the same.Type: GrantFiled: April 15, 2009Date of Patent: November 29, 2011Assignee: Dalim Biotech Co., Ltd.Inventor: Hwal Suh
-
Publication number: 20110275700Abstract: The present invention relates to biodegradable biocompatible polyketals, methods for their preparation, and methods for treating animals by administration of biodegradable biocompatible polyketals. In one aspect, a method for forming the biodegradable biocompatible polyketals comprises combining a glycol-specific oxidizing agent with a polysaccharide to form an aldehyde intermediate, which is combined with a reducing agent to form the biodegradable biocompatible polyketal. The resultant biodegradable biocompatible polyketals can be chemically modified to incorporate additional hydrophilic moieties. A method for treating animals includes the administration of the biodegradable biocompatible polyketal in which biologically active compounds or diagnostic labels can be disposed. The present invention also relates to chiral polyketals, methods for their preparation, and methods for use in chromatographic applications, specifically in chiral separations.Type: ApplicationFiled: April 26, 2011Publication date: November 10, 2011Applicant: THE GENERAL HOSPITAL CORPORATIONInventor: Mikhail I. Papisov
-
Publication number: 20110275135Abstract: Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from Alicyclobacillus acidocaldarius are provided. Further provided are methods for modulating or altering recombination inside or outside of a cell using isolated and/or purified polypeptides and/or nucleic acid sequences from Alicyclobacillus acidocaldarius.Type: ApplicationFiled: May 5, 2010Publication date: November 10, 2011Applicant: Battelle Energy Alliance, LLCInventors: Brady D. Lee, Deborah T. Newby, Jeffrey A. Lacey, David N. Thompson, Vicki S. Thompson, William A. Apel, Francisco F. Roberto, David W. Reed
-
Publication number: 20110268818Abstract: The invention provides compositions comprising a lipocalin, such as NGAL, and a mammalian siderophore that are useful as iron chelators and iron donors. The invention also provides mammalian siderophore compounds of Formula (I): The invention further provides, methods of treatment and methods of diagnosis.Type: ApplicationFiled: September 18, 2009Publication date: November 3, 2011Inventors: Jonathan Barasch, Shixian Deng, Guanhu Bao, Donald W. Landry
-
Publication number: 20110262366Abstract: The present invention provides compounds for targeting endothelial cells, tumor cells or other cells that express the NP-1 receptor, compositions containing the same and methods for their use. Additionally, the present invention includes diagnostic, therapeutic and radiotherapeutic compositions useful for visualization, therapy or radiotherapy.Type: ApplicationFiled: December 15, 2010Publication date: October 27, 2011Applicant: BRACCO INTERNATIONAL B.V.Inventors: Mathew A. Von Wronski, Edmund R. Marinelli, Adrian D. Nunn, Radhakrishna K. Pillai, Kondareddiar Ramalingam, Michael F. Tweedle, Karen E. Linder, Palaniappa Nanjappan, Natarajan Raju, Feng Yan, Michel Schneider
-
Publication number: 20110263696Abstract: Compositions comprising proanthocyanidin compositions (e.g. those extracted from cinnamomum species) that are observed to bind tau and inhibit its aggregation as well as methods for making and using such compositions are disclosed. In certain embodiments of the invention, the proanthocyanidins can be used as a probe to identify and/or characterize tau isoforms in a variety of contexts. In other embodiments of the invention, these compositions are used in methods designed to treat neurological disorders associated with tau aggregation (e.g. Alzheimer's disease).Type: ApplicationFiled: March 31, 2008Publication date: October 27, 2011Inventors: Donald J. Graves, John Lew
-
Publication number: 20110256303Abstract: A process for cross-linking proteins, according to which the crosslinking agent is dihydroxyacetone and the proteins are chosen from proteins from animal tissues, from milk or from blood, such as in particular casein, gelatin or collagen; proteins from cereals, such as in particular maize, wheat or rice proteins; protein from high-protein plants, such as in particular pea, alfalfa, lupin, barley, millet or sorghum proteins; proteins from oleaginous plants, such as in particular soybean proteins, for instance soybean cakes, rapeseed or flax proteins, for instance rapeseed cakes, sunflower, groundnut or cotton proteins; and proteins from tubers, such as in particular from potato or manioc.Type: ApplicationFiled: June 27, 2011Publication date: October 20, 2011Applicant: ROQUETTE FRERESInventors: Daniel WILS, Catherine FOUACHE
-
Publication number: 20110245466Abstract: The invention concerns the method of production of a polyanionic macromolecule which is a protein built, among others, form polar amino acids (such as lysine, arginine, aspartic acid, glutamic acid), characteristic in that, that as a result of the reaction between amine groups and the cyclic anhydride of dicarboxylic acid, the charge changes towards more negatively charged carrier. This reaction gives rise to better therapeutic properties of macromolecules modified in this way.Type: ApplicationFiled: October 23, 2009Publication date: October 6, 2011Inventors: Janusz Boratynski, Mohamed Salah Omar Megahed, Urszula Kanska, Dmitry Nevozhay, Joanna Wietrzyk
-
Publication number: 20110229982Abstract: The object of the present invention is to provide a method for immobilizing the SpA protein on the surface of a substrate with high density without causing dimerization. The following method solves the object. That is, the method for binding a protein to a surface of a substrate, comprising steps (A) to (B): step (A) of preparing said protein to the surface, step (B) of supplying said protein to the surface, wherein said protein consists of a Protein A or at least one domain of A to E of said Protein A, and said protein comprises C-terminal modified amino acid sequence represented by SEQ ID:1(SFNRSEC).Type: ApplicationFiled: March 29, 2011Publication date: September 22, 2011Applicant: Panasonic CorporationInventors: Jin MURAOKA, Takachika Azuma, Akikazu Murakami
-
Publication number: 20110230391Abstract: The invention relates to the Fc? receptor (Fc-gamma receptor) for use in treating multiple sclerosis, wherein the multiple sclerosis is a B cell mediated form of multiple sclerosis and/or an autoantibody driven form of multiple sclerosis. The invention relates to pharmaceutical compositions containing the Fc? receptor (Fc-gamma receptor) for use in treating multiple sclerosis, wherein the multiple sclerosis is a B cell mediated form of multiple sclerosis and/or an autoantibody driven form of multiple sclerosis.Type: ApplicationFiled: September 2, 2009Publication date: September 22, 2011Inventors: Peter Buckel, Uwe Jacob
-
Publication number: 20110223151Abstract: The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing said conjugates, to pharmaceutical compositions comprising said conjugates and to the use of the conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.Type: ApplicationFiled: August 6, 2009Publication date: September 15, 2011Applicant: Novo Nordisk Health Care AGInventors: Carsten Behrens, Patrick William Garibay, Soren Østergaard, Henrik Sune Andersen, Johansen Nils Langeland, Peschke Bernd, Bak Sonja
-
Publication number: 20110224143Abstract: The invention relates to Nucleobindin-1 (NUCB1) protein variants that are capable of disaggregating amyloid fibrils as well as inhibiting the formation of fibrils in the presence of physiological concentrations of calcium. Isolated NUCB1 protein variants, nucleic acids encoding the protein variants, cells comprising the isolated nucleic acids, pharmaceutical compositions and kits comprising the variants, methods of making the variants, and therapeutic uses of the variants are provided.Type: ApplicationFiled: July 16, 2009Publication date: September 15, 2011Applicants: The Rockerfeller University, THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORKInventors: Thomas P. Sakmar, Santosh T. Menon, Neeraj Kapoor, Ruchi Gupta, Dan Raleigh
-
Publication number: 20110217750Abstract: An activatable functionalised Nth generation dendrimer having: a core comprising a first monomer having at least two carboxylic acid functional groups; and N successive generations, where N=0 to 10, wherein each generation comprises: a second monomer having at least two alcohol functional groups, wherein at least one alcohol group is bonded to a carboxylic acid group of the first monomer of the prior generation, and an additional first monomer attached to a second alcohol function group of said second monomer of that generation; and the final generation having attached thereto at said second alcohol functional group of said second monomer, a moiety having a dicarboxylic acid functional group, activatable by treatment with a carboxylic acid activating reagent such that reactivity of the carboxylic acid functional group is increased. The dendrimer, when activated, may be used in applications such as polymer crosslinking and/or nanoshell production.Type: ApplicationFiled: March 19, 2009Publication date: September 8, 2011Applicant: NATIONAL UNIVERSITY OF IRELAND, GALWAYInventors: Abhay Pandit, Gildas Rethore, Hemantkumar Naik
-
Publication number: 20110217732Abstract: The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with post-translational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engineered mutant of ?-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.Type: ApplicationFiled: October 21, 2010Publication date: September 8, 2011Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: LINDA HSIEH-WILSON, NELLY KHIDEKEL, HWAN-CHING TAI, SABINE ARNDT
-
Patent number: 8008430Abstract: A high molecular weight, water-soluble polymer comprising pendant salicylic acid groups and having a weight average molecular weight of at least about 2,000,000 daltons and use of the polymer for clarifying red mud-containing liquors generated in the Bayer process for the recovery of alumina from bauxite.Type: GrantFiled: August 17, 2006Date of Patent: August 30, 2011Assignee: Nalco CompanyInventors: Murat Quadir, Everett C. Phillips, Larry E. Brammer, Jr., Robert P. Mahoney, John D. Kildea, Manian Ramesh, John T. Malito
-
Publication number: 20110207154Abstract: The present invention is directed toward a method for determination of marinobufagenin concentration in a body specimen through conjugation of marinobufagenin to a suitable protein, thereby creating a conjugate which will trigger an antibody response in a host. The conjugated marinobufagenin is immunogenic. The antibodies so produced may be employed in an ELISA test to ascertain the concentration of marinobufagenin in a body specimen. A number of unique compounds are created in the process and are disclosed. An ELISA assay may be employed.Type: ApplicationFiled: December 21, 2010Publication date: August 25, 2011Applicant: SCOTT & WHITE HEALTHCAREInventors: JULES B. PUSCHETT, Daniel Romo, Luc R. Berghman, Daad Ali Abi-Ghanem, Xinzhong Lai